Ann: Statement by CEO on Sale of Shares, page-18

As per the plan I will keep on banging away. Todays email:

Dear Mr Duthy,

Following on from my email of the 2nd of November I like to bring to your attention how out of step Sirtex is in regards to its peers and the release of trading updates and/or forecasts.

I still find it inconceivable that Sirtex is not prepared to release its quarterly sales or full year forecasts. A quick review of Sirtex peers in the S&P/ASX 200 Health Care Index (mid caps) clearly shows that Sirtex is at best lazy - or at worst - happy to treat shareholders with contempt. Sirtex and Mayne Pharmaceuticals are the only two mid cap companies who do not give forecasts or trading updates. Listed below are your mid cap peers in the sector who are more than happy to give guidance.

As highlighted last week when directors sell it creates a uncertainty as shareholders "not inside the tent" are left to question the performance of the business. This nervousness can clearly be eliminated by simply giving forecasts and or trading updates.

I strongly urge that you and the Board quickly implement greater transparency and restore retail shareholder trust in this area by releasing a trading update and or forecast as soon as possible.

Regards

	Column 1	Column 2	Column 3
1
2
3
4	ASX Code	Company	Mkt Cap
5	FPH	Fisher & Paykel Health	4.8bn
6	HSO	Healthscope Ltd	3.8bn
7	ANN	Ansell Ltd	3.2bn
8	EBO	Ebos Group	2.4bn
9	PRX	Primary Health Care	1.9bn
10	SIP	Sigma Pharmaceutical	1.4bn
11	REG	Regis Healthcare	1.2bn